
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences is a clinical-stage biopharmaceutical company with a promising pipeline of product candidates aimed at addressing rare endocrine disorders. Their lead candidate, TA-ERT, has shown strong results in reducing biomarkers and preserving cognitive outcomes in patients with MPS IIIB, and recent FDA interactions have confirmed the potential for accelerated approval. With fast track, breakthrough therapy, and orphan drug designations, and a potential peak sales of over $150 million, Spruce Biosciences is well poised for success in the ultra-rare disease market.
Bears say
Spruce Biosciences is currently overvalued, with a 12-month price objective of $220 per share. The company's high risk factors include potential delays and rejections for FDA approval, as well as potential issues with commercial success and competition in the market. With an estimated total enterprise value of $236M and a total firm value of $280M, the stock may not be a sound investment choice in the long term.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares